This Article Full Text Full Text (PDF) All Versions of this Article: 105/11/1380    most recent hc1102.105258v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loennechen, J. P. Articles by Ellingsen, O. Search for Related Content PubMed PubMed Citation Articles by Loennechen, J. P. Articles by Ellingsen, O. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Hazardous Substances DB LOSARTAN POTASSIUM Related Collections Congestive Cardiovascular Pharmacology ACE/Angiotension receptors Animal models of human disease Calcium cycling/excitation-contraction coupling Gene expression Hypertrophy Echocardiography

(Circulation. 2002;105:1380.)
© 2002 American Heart Association, Inc.

Basic Science Reports

Effects of Cariporide and Losartan on Hypertrophy, Calcium Transients, Contractility, and Gene Expression in Congestive Heart Failure

Jan P. Loennechen, MD; Ulrik Wisløff, MSc, PhD; Geir Falck, MD, PhD; Øyvind Ellingsen, MD,PhD

From the Department of Physiology and Biomedical Engineering, Norwegian University of Science and Technology, Trondheim, Norway.

Correspondence to Dr Ellingsen, Department of Physiology and Biomedical Engineering, Norwegian University of Science and Technology, Medical Technology Research Center, Olav Kyrres gate 3, N-7489 Trondheim, Norway. E-mail oyvinde{at}medisin.ntnu.no

Background— The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure.

Methods and Results— Female Sprague-Dawley rats with large myocardial infarctions and sham controls were randomized to losartan, cariporide, or placebo after 7 days and treated for 49 days. Cardiac function was assessed by echocardiography and measurement of left ventricular pressures, and gene expression was assessed by competitive reverse transcription–polymerase chain reaction. Cell dimensions, shortening, and relaxation were determined by videomicroscopy and calcium transients by fura 2. Losartan reduced postinfarction systolic and diastolic left ventricular dilation (by 24% and 31%, respectively), left and right ventricular weight (by 22% and 26%, respectively), and cardiomyocyte hypertrophy length and width (by 62% and 54%, respectively). Induction of myocardial atrial natriuretic peptide decreased 66%. Cariporide did not affect postinfarction hypertrophy or atrial natriuretic peptide. Losartan and cariporide respectively improved reduced cellular contractility (55% and 30%) and reduced elevated systolic (86% and 27%) and diastolic (49% and 43%) calcium. Losartan and cariporide respectively reduced prolonged time to 50% relaxation (66% and 25%) and time to 50% calcium reduction (55% and 53%).

Conclusions— Losartan and cariporide improve cardiomyocyte contractility and calcium regulation in chronic heart failure. Losartan has salutary effects on postinfarction remodeling and gene expression, whereas cariporide is neutral.

Key Words: myocardial infarction • echocardiography • myocytes • calcium • genes

This article has been cited by other articles:

				O. J. Kemi, M. A. Hoydal, P. M. Haram, A. Garnier, D. Fortin, R. Ventura-Clapier, and O. Ellingsen Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan Cardiovasc Res, October 1, 2007; 76(1): 91 - 99. [Abstract] [Full Text] [PDF]

				U. Wisloff, A. Stoylen, J. P. Loennechen, M. Bruvold, O. Rognmo, P. M. Haram, A. E. Tjonna, J. Helgerud, S. A. Slordahl, S. J. Lee, et al. Superior Cardiovascular Effect of Aerobic Interval Training Versus Moderate Continuous Training in Heart Failure Patients: A Randomized Study Circulation, June 19, 2007; 115(24): 3086 - 3094. [Abstract] [Full Text] [PDF]

				H. E. Cingolani and I. L. Ennis Sodium-Hydrogen Exchanger, Cardiac Overload, and Myocardial Hypertrophy Circulation, March 6, 2007; 115(9): 1090 - 1100. [Full Text] [PDF]

				T.-M. Lee, M.-S. Lin, T.-F. Chou, and N.-C. Chang Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1281 - H1289. [Abstract] [Full Text] [PDF]

				V. Bassien-Capsa, J.-C. Fouron, B. Comte, and A. Chorvatova Structural, functional and metabolic remodeling of rat left ventricular myocytes in normal and in sodium-supplemented pregnancy Cardiovasc Res, February 1, 2006; 69(2): 423 - 431. [Abstract] [Full Text] [PDF]

				B. I. Gustafsson, K. Tommeras, I. Nordrum, J. P. Loennechen, A. Brunsvik, E. Solligard, R. Fossmark, I. Bakke, U. Syversen, and H. Waldum Long-Term Serotonin Administration Induces Heart Valve Disease in Rats Circulation, March 29, 2005; 111(12): 1517 - 1522. [Abstract] [Full Text] [PDF]

				L. Chen, C. X. Chen, X. T. Gan, N. Beier, W. Scholz, and M. Karmazyn Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H381 - H387. [Abstract] [Full Text] [PDF]